177 related articles for article (PubMed ID: 36496167)
1. Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy.
Chen J; You X; Wu W; Guo G; Lin R; Ke M; Huang P; Lin C
Eur J Pharm Sci; 2023 Feb; 181():106349. PubMed ID: 36496167
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy.
Chen Y; Ke M; Fang W; Jiang Y; Lin R; Wu W; Huang P; Lin C
Eur J Pharm Sci; 2024 Mar; 194():106707. PubMed ID: 38244810
[TBL] [Abstract][Full Text] [Related]
3. Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy.
Pillai VC; Shah M; Rytting E; Nanovskaya TN; Wang X; Clark SM; Ahmed MS; Hankins GDV; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2022 Jan; 88(1):271-281. PubMed ID: 34185331
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester.
Shenkoya B; Atoyebi S; Eniayewu I; Akinloye A; Olagunju A
Front Pediatr; 2021; 9():734122. PubMed ID: 34616699
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of Physiologically Based Pharmacokinetic Model of Levetiracetam to Predict Exposure and Dose Optimization in Pediatrics.
Shao W; Shen C; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
J Pharm Sci; 2023 Oct; 112(10):2667-2675. PubMed ID: 37023853
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.
Liu XI; Momper JD; Rakhmanina N; van den Anker JN; Green DJ; Burckart GJ; Best BM; Mirochnick M; Capparelli EV; Dallmann A
J Clin Pharmacol; 2020 Feb; 60(2):240-255. PubMed ID: 31489678
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-Based Pharmacokinetic Modeling of Tenofovir Disoproxil Fumarate in Pregnant Women.
Zhang X; Luo T; Yang H; Ma WY; He Q; Xu M; Yang Y
Curr Drug Metab; 2023; 23(14):1115-1123. PubMed ID: 36718061
[TBL] [Abstract][Full Text] [Related]
9. Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations.
Wang R; Wang T; Han X; Chen M; Li S
Xenobiotica; 2024 Mar; 54(3):116-123. PubMed ID: 38344757
[TBL] [Abstract][Full Text] [Related]
10. Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.
Balhara A; Kumar AR; Unadkat JD
J Clin Pharmacol; 2022 Sep; 62 Suppl 1(Suppl 1):S94-S114. PubMed ID: 36106781
[TBL] [Abstract][Full Text] [Related]
11. Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Zheng L; Tang S; Tang R; Xu M; Jiang X; Wang L
Clin Pharmacokinet; 2021 May; 60(5):623-635. PubMed ID: 33251573
[TBL] [Abstract][Full Text] [Related]
12. A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.
De Sousa Mendes M; Lui G; Zheng Y; Pressiat C; Hirt D; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Urien S; Benaboud S
Clin Pharmacokinet; 2017 May; 56(5):537-550. PubMed ID: 27766562
[TBL] [Abstract][Full Text] [Related]
13. Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime.
Liu XI; Green DJ; van den Anker J; Ahmadzia HK; Burckart GJ; Dallmann A
Clin Pharmacokinet; 2024 Jan; 63(1):69-78. PubMed ID: 37962827
[TBL] [Abstract][Full Text] [Related]
14. The development of a pregnancy PBPK Model for Bisphenol A and its evaluation with the available biomonitoring data.
Sharma RP; Schuhmacher M; Kumar V
Sci Total Environ; 2018 May; 624():55-68. PubMed ID: 29247905
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach.
Van Der Heijden JEM; Van Hove H; Van Elst NM; Van Den Broek P; Van Drongelen J; Scheepers HCJ; De Wildt SN; Greupink R
Am J Obstet Gynecol; 2024 May; ():. PubMed ID: 38763343
[TBL] [Abstract][Full Text] [Related]
16. Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine.
He L; Ke M; Wu W; Chen J; Guo G; Lin R; Huang P; Lin C
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365185
[TBL] [Abstract][Full Text] [Related]
17. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Peng J; Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
[TBL] [Abstract][Full Text] [Related]
18. PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus.
Szeto KX; Le Merdy M; Dupont B; Bolger MB; Lukacova V
AAPS J; 2021 Jun; 23(4):89. PubMed ID: 34169370
[TBL] [Abstract][Full Text] [Related]
19. Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome.
Anoshchenko O; Milad MA; Unadkat JD
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1057-1070. PubMed ID: 34273255
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Caffeine Disposition in Pregnancy.
Darakjian LI; Kaddoumi A
Mol Pharm; 2019 Mar; 16(3):1340-1349. PubMed ID: 30689395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
